Fullerton neurology and Headache Center regularly perform research in many neurological diseases.Why should I participate in a clinical trial?

Help researchers uncover better ways to prevent, diagnose, treat and understand various neurological diseases.
Clinical trials provide access to treatment which are otherwise unavailable.

We are currently recruiting for the following trials:


This is a prospective five-year study to evaluate the long term safety profile of LEMTRADA in patients with relapsing forms of multiple sclerosis (RMS). The “adverse events of special interest” that are monitored include serious infections, malignancies, and auto-immune mediated conditions.

• Diagnosis of RMS
• Initiated LEMTRADA treatment for first time within 8 weeks of study entry

The purpose of this study is to evaluate the efficacy and safety of Gantenerumab compared to placebo in patients with prodromal to mild Alzheimer’s disease. The medication is injected subcutaneously once a month. This is a four year trial.
Outcomes include the change in amyloid in the brain as measured by amyloid PET scans as well as changes in cognition and daily functioning.

• Ages 50 to 90
• Probable or prodromal Alzheimer’s disease
• If patient is receiving medications, a stable dosing regimen for at least 3 months

What is the LUCIDITY Study?

The aim of the LUCIDITY Study is to assess the safety and effectiveness of an investigation drug in men and women with mild AD. The investigational drug will be compared with a placebo, which looks similar to the investigational drug but contains no active medication.

Who can take part in the LUCIDITY Study?

Approximately 180 people in 64 study center across the United States, Canaf=da, UK, Hungary, Belgium and Poland are expected to take part. You may be able to participate if you:

• Are under 90 years of age
• Have been diagnosed with AD
• Have a caregiver who can accompany you to the study center

There are other criteria that you will need to meet to qualify, which the study team will discuss with you.

How long will the LUCIDITY Study last?

The study is expected to last up to 36 weeks, during which you will be asked to attend the study center 5 times to undergo medical tests and assessments. The study is made up of three parts:

Part 1: Screening – up to 6 weeks before the start of part 2, you will be invited to attend a screening visit where the study team will perform tests to determine your suitability.
Part 2: Study treatment – if eligible, you will take the study drug twice a day for 26 weeks.
Part 3: Follow –up – 4 weeks after your last visit to the study center, you/your caregiver will receieve a telephone call from the study team to check on your health and well-being.

What happens during visits to the study center?

At each visit, you will undergo tests and assessments to check your health and determine how your body is responding to the study drug. The following assessments will occur during the study:

• Questions about you, your health, medical history, current and previous medications
• Physical and neurological examinations
• Measurements of height, weight, blood pressure and pulse
• Eye exam (if necessary)
• ECG (measures the rate and regularity of your heart beats)
• MRI scan (show image of tissues and organs inside your body)
• PET scan (shows how your tissues and organs are functioning)
• Blood tests
• Assessment of your condition and how it is affecting your life

Participation is entirely voluntary and you can withdraw at any time. Contacting us does not mean that you are obligated to join the study or that you will be eligible to participate.

This is a 44 week double blind, placebo controlled, clinical trial to evaluate the efficacy of the study drug, NBI-98854, in pediatric subjects with Tourette syndrome. NBI-98854 is an oral drug taken once a day, nightly.

• Males and females ages 6-17
• DSM-IV or -5 Diagnosis of Tourette Syndrome
• If on medications for Tourette Syndrome, must be on these medications for a minimum of 30 days before Day 1 of clinical trial

A 128 week, double blind study, assessing the safety, tolerability and Efficacy of LY3303560 in patients with early symptomatic Alzheimer’s Disease. The study drug is administered via IV infusion and is compared to a placebo.

• Men or women, ages 60-85
• A gradual and progressive change in memory function

Subcutaneous administration of ofatumumab to either the abdominal region or the thigh which are two injections sites allowed. Secondary objective is assessing during the 12 weeks potential differences in ofatumumab anti-drug antibody formation between the Pre Filled Syringe and Auto injector devices as well as between abdomen and thigh injection sites.


  • 18-55
  • Diagnosis of MS
  • Documentation of 1 relapse or a new enhancing lesion

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine


  • Participants must be using a medically acceptable and effective method of birth control during the course of the entire study,
  • At least a 1-year history of migraine with or without aura consistent with a diagnosis
  • Age of the participant at the time of migraine onset < 50 years • History of 4 to 14 migraine days per month on average in the 3 months prior to the first visit
For information or to enroll in a trial, please contact Alexandra Vasquez by phone at (714) 738-3845